No­var­tis nabs pri­or­i­ty re­view for a block­buster-to-be aimed at NSCLC niche — de­light­ing In­cyte ex­ecs

In­cyte fi­nal­ly has some good news to share about one drug it’s dis­cov­ered that’s not Jakafi — al­beit one that doesn’t be­long to it any­more.

FDA reg­u­la­tors have ac­cept­ed cap­ma­tinib, an or­phan and “break­through” MET in­hibitor, for pri­or­i­ty re­view. The hon­or tech­ni­cal­ly goes to No­var­tis, which li­censed world­wide de­vel­op­ment and com­mer­cial­iza­tion rights to the drug back in 2009.

But that didn’t stop In­cyte from brag­ging about it in a re­lease, re­mind­ing in­vestors that if every­thing goes well, it’s el­i­gi­ble for $500 mil­lion-plus in mile­stones as well as roy­al­ties up to 14% of glob­al sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER